Ruth Aranda

The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients

Jill Hallin, Lars D. Engstrom, Lauren Hargis et al. · Cancer Discovery · 2019 · 1.3K citations · Full text

Medicine, Oncology, Pharmacology +17

MRTX1719 Is an MTA-Cooperative PRMT5 Inhibitor That Exhibits Synthetic Lethality in Preclinical Models and Patients with <i>MTAP</i> -Deleted Cancer

Lars D. Engstrom, Ruth Aranda, Laura Waters et al. · Cancer Discovery · 2023 · 194 citations · Full text

Medicine, Oncology, Pharmacology +10

The KRASG12C Inhibitor MRTX849 Reconditions the Tumor Immune Microenvironment and Sensitizes Tumors to Checkpoint Inhibitor Therapy

David M. Briere, Shuai Li, Andrew Calinisan et al. · Molecular Cancer Therapeutics · 2021 · 167 citations · Full text

Medicine, Immunology, Oncology +17

Fragment-Based Discovery of MRTX1719, a Synthetic Lethal Inhibitor of the PRMT5•MTA Complex for the Treatment of <i>MTAP</i> -Deleted Cancers

Christopher R. Smith, Ruth Aranda, Thomas P. Bobinski et al. · Journal of Medicinal Chemistry · 2022 · 151 citations · Full text

Pharmacy, Oncology, Pharmacology +15

Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring <i>MET</i> Exon 14 Mutations and Overcomes Mutation-mediated Resistance to Type I MET Inhibitors in Nonclinical Models

Lars D. Engstrom, Ruth Aranda, Matthew Lee et al. · Clinical Cancer Research · 2017 · 147 citations · Full text

Medicine, Oncology, Pharmacology +14